CA2528627A1 - Methods for treating protein aggregation disorders - Google Patents

Methods for treating protein aggregation disorders Download PDF

Info

Publication number
CA2528627A1
CA2528627A1 CA002528627A CA2528627A CA2528627A1 CA 2528627 A1 CA2528627 A1 CA 2528627A1 CA 002528627 A CA002528627 A CA 002528627A CA 2528627 A CA2528627 A CA 2528627A CA 2528627 A1 CA2528627 A1 CA 2528627A1
Authority
CA
Canada
Prior art keywords
group
protein
alkyl
protein aggregation
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002528627A
Other languages
English (en)
Inventor
Patrick Tremblay
Richard Mclaughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bellus Health International Ltd
Original Assignee
Neurochem (International) Limited
Patrick Tremblay
Richard Mclaughlin
Neurochem, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem (International) Limited, Patrick Tremblay, Richard Mclaughlin, Neurochem, Inc. filed Critical Neurochem (International) Limited
Publication of CA2528627A1 publication Critical patent/CA2528627A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Saccharide Compounds (AREA)
CA002528627A 2003-06-23 2004-06-21 Methods for treating protein aggregation disorders Abandoned CA2528627A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US48091803P 2003-06-23 2003-06-23
US60/480,918 2003-06-23
US51201703P 2003-10-17 2003-10-17
US60/512,017 2003-10-17
US87161304A 2004-06-18 2004-06-18
US10/871,613 2004-06-18
PCT/IB2004/002405 WO2005000288A2 (fr) 2003-06-23 2004-06-21 Methods for treating protein aggregation disorders

Publications (1)

Publication Number Publication Date
CA2528627A1 true CA2528627A1 (fr) 2005-01-06

Family

ID=33556419

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002528627A Abandoned CA2528627A1 (fr) 2003-06-23 2004-06-21 Methods for treating protein aggregation disorders

Country Status (7)

Country Link
EP (1) EP1646375A2 (fr)
JP (1) JP2007521255A (fr)
AU (1) AU2004251511A1 (fr)
CA (1) CA2528627A1 (fr)
IL (1) IL172249A0 (fr)
MX (1) MXPA05013692A (fr)
WO (1) WO2005000288A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937239A2 (fr) * 2005-09-30 2008-07-02 Neurochem (International) Limited Méthodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques
CN101501694B (zh) * 2006-08-04 2011-11-30 英国龙沙生物医药股份有限公司 用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法
CA2723440A1 (fr) * 2008-05-05 2009-11-12 Tiltan Pharma Ltd. Sulfobetaines destinees a des fins therapeutiques
CA2886683A1 (fr) * 2011-05-26 2012-11-29 Glycoregimmune, Inc. Carrying On Business As Gri Bio, Inc. Derives d'acide sulfonique, d'acide phosphonique et d'acide carbonique contenant un groupe amino ou ammonium et leur utilisation medicale
EP2739606B1 (fr) 2011-05-26 2016-04-27 Jado Technologies GmbH Dérivés d'amino et ammonium substitués d'hydroxy et utilisation médicale associée
EP3597634A1 (fr) 2011-05-26 2020-01-22 GRI Bio, Inc. Acide sulfonique contenant de l'amino ou de l'ammonium oxygéné, acide phosphonique et dérivés d'acide carboxylique et leur utilisation médicale
WO2018156845A1 (fr) * 2017-02-24 2018-08-30 Alzheon, Inc. Méthodes de traitement d'affections neurodégénératives
CN112912732A (zh) * 2018-08-03 2021-06-04 香港大学 用于淀粉样蛋白原纤维、淀粉样蛋白斑块、rna和核仁的检测和成像的组合物和方法
CN114615973A (zh) * 2019-11-08 2022-06-10 中央硝子株式会社 选择性杀灭含有蛋白质聚集体的细胞的方法、其试剂盒、蛋白质错误折叠病治疗药及自血液制品中去除蛋白质聚集体的制剂
CN111500729B (zh) * 2020-05-14 2022-02-01 中国人民解放军总医院 血浆lnc-SCA7在制备判断患者是否对新辅助化疗敏感的生物标志物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0572560B1 (fr) * 1991-02-22 2003-01-29 SHAPIRO, Howard, K. Utilisation de composes pharmaceutiques pour le traitement de troubles associes a des affections neurologiques et a des symptomes apparentes de fa on etiologique
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
CA2250780A1 (fr) * 1996-04-10 1997-10-16 The Regents Of The University Of California Correction des defaillances genetiques a l'aide de chaperons chimiques
EP1001987B1 (fr) * 1997-08-01 2010-12-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition et nouveau procede pour depister les maladies dues a la formation d'agregats de proteines ou de fibrilles du type amyloide
CA2320556A1 (fr) * 1999-09-29 2001-03-29 Queen's University At Kingston N',n'-dichloro-omega-aminoacides et leurs derives et leurs utilisations
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US20020155172A1 (en) * 2000-04-07 2002-10-24 Junying Yuan Methods and compounds for decreasing cell toxicity or death
GB0117326D0 (en) * 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
WO2004058239A1 (fr) * 2002-12-24 2004-07-15 Neurochem (International) Limited Formulations therapeutiques destinees au traitement de maladies liees au peptide beta-amyloide

Also Published As

Publication number Publication date
IL172249A0 (en) 2006-04-10
JP2007521255A (ja) 2007-08-02
MXPA05013692A (es) 2006-03-13
EP1646375A2 (fr) 2006-04-19
AU2004251511A1 (en) 2005-01-06
WO2005000288A3 (fr) 2005-05-06
WO2005000288A2 (fr) 2005-01-06

Similar Documents

Publication Publication Date Title
US20050215562A1 (en) Methods for treating protein aggregation disorders
US11046650B2 (en) Deuterated compounds and uses thereof
KR101124935B1 (ko) 아밀로이드 관련 질환의 치료 방법 및 조성물
Jakubowski et al. Interactions between curcumin derivatives and amyloid-β fibrils: insights from molecular dynamics simulations
AU2017317529A1 (en) Aldehyde trapping compounds and methods of use thereof
Lu et al. Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line
CA2556270A1 (fr) Composes d'aryle nitrone substitues en position 2 et substitues en position 4
US20030083266A1 (en) Treatment of ischemic brain injuries with brain targeted antioxidant compounds
EP4335517A2 (fr) Administration et dosage de diaminophénothiazines
JP2008525425A (ja) アミロイド関連疾患を治療するための方法および組成物
IL172194A (en) A compound and pharmaceutical composition containing it for the treatment or prevention of amyloid-dependent diseases
JP2008520647A (ja) Ｃｎｓおよびアミロイド関連疾患治療のための化合物
MX2007005507A (es) Metodos y composiciones fluoradas para el tratamiento de padecimientos relacionados con amiloides.
CA2528627A1 (fr) Methods for treating protein aggregation disorders
GB2571978A (en) Uses, compositions and methods
Giordano et al. Inhibition of Amyloid Peptide Fragment Aβ25–35 Fibrillogenesis and Toxicity by N‐Terminal β‐Amino Acid‐Containing Esapeptides: Is Taurine Moiety Essential for In Vivo Effects?
WO2022099412A1 (fr) Dérivés d'acide 3-amino-1-propanesulfonique enrichis en isotopes pour le traitement d'une maladie cérébrovasculaire
JP2002527350A (ja) 発作を治療するのに有用なアミノ酸誘導体
Omran et al. Synthesis and in vitro evaluation of novel pro-drugs for the treatment of nephropathic cystinosis
CA3097510A1 (fr) Utilisation de composes thiol pour traiter une maladie neurologique
Korshavn Mechanistic and Structural Insights into the Chemical Modulation of Amyloid Aggregation
US20110015139A1 (en) Histidine related compounds for identifying and blocking amyloid beta ion channels
Greig et al. Dissociation between the potent β-amyloid protein pathway inhibition and cholinergic actions of the Alzheimer drug candidates phenserine and cymserine
Akoury Molecular mechanisms of Tau protein aggregation inhibition
EP1937239A2 (fr) Méthodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques

Legal Events

Date Code Title Description
FZDE Discontinued